Results 11 to 20 of about 4,340 (195)
Cancer Management and Research, 2018 Pamela B Allen, Mary Jo Lechowicz Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA Abstract: Peripheral T-cell lymphomas (PTCLs) are an aggressive and diverse group of lymphomas with a T-cell origin ...
Allen PB, Lechowicz MJ
doaj +6 more sources
Apoptotic effect of Belinostat (PXD101) on MCF-7 cancer cells [PDF]
Annals of Medical Research, 2021 Aim: Breast cancer continues to be the most common type of cancer among women. Recent development in epigenomics hashighlighted key mechanisms in which epigenetic regulation contributes to cancer treatment. Epigenetic modulating drugs promises novel approaches targeting cancer treatment. Belinostat is a histone deacetylase inhibitor approved by the U.S.
TUNCER, Zeliha +3 more
openaire +3 more sources
Anticancer clinical efficiency and stochastic mechanisms of belinostat
Biomedicine & Pharmacotherapy, 2023 Cancer progression is strongly affected by epigenetic events in addition to genetic modifications. One of the key elements in the epigenetic control of gene expression is histone modification through acetylation, which is regulated by the synergy between histone acetyltransferases (HATs) and histone deacetylases (HDACs).
Nasreddine El Omari +8 more
openaire +3 more sources
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. [PDF]
PLoS ONE, 2013 UnlabelledBelinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for non-hematologic malignancies.
Ling-Zhi Wang +16 more
doaj +2 more sources
The Development of an Effective Synthetic Route of Belinostat
Organic Process Research & Development, 2016 A practical synthetic route of belinostat is reported. Belinostat was obtained via a five-step process starting from benzaldehyde and including addition reaction with sodium bisulfite, sulfochlorination with chlorosulfonic acid, sulfonamidation with aniline, Knoevenagel condensation, and the final amidation with hydroxylamine.
Xuefei Bao +4 more
openaire +2 more sources
Tomography, 2023 Histone deacetylase inhibitors (HDACis) are drugs that target the epigenetic state of cells by modifying the compaction of chromatin through effects on histone acetylation.
Chi-Ming Chang +7 more
doaj +2 more sources
Monitoring the effect of belinostat in solid tumors by H4 acetylation [PDF]
APMIS, 2008 Histone deacetylase (HDAC) inhibition is a novel entity in medical oncology, and several HDAC inhibitors are in clinical trials. One of them is the hydroxamic acid belinostat (PXD101) that has demonstrated therapeutic efficacy for several clinical indications.
Marquard, L. +5 more
openaire +3 more sources
BMC Cancer, 2012 Background Treatment options for pancreatic ductal adenocarcinoma (PDAC) are limited. Histone deacetylase inhibitors are a new and promising drug family with strong anticancer activity. The aim of this study was to examine the efficacy of in vitro and in
Dovzhanskiy Dmitriy I +7 more
doaj +2 more sources
Retraction Note: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer [PDF]
Journal of Cancer Research and Clinical OncologyDaniel Chan +8 more
doaj +4 more sources
Journal of Cancer Research and Clinical Oncology, 2013 Purpose Advanced thyroid cancer responds poorly to most therapies. New therapies and combinations are needed. The aim of this study was to examine both in vitro and in vivo activity of two relatively new histone deacetylase inhibitors (HDACIs ...
Daniel Chan +8 more
doaj +5 more sources